JP2008521933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521933A5 JP2008521933A5 JP2007544570A JP2007544570A JP2008521933A5 JP 2008521933 A5 JP2008521933 A5 JP 2008521933A5 JP 2007544570 A JP2007544570 A JP 2007544570A JP 2007544570 A JP2007544570 A JP 2007544570A JP 2008521933 A5 JP2008521933 A5 JP 2008521933A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- solution
- salt
- crystalline
- seed crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 description 48
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000013078 crystal Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- 150000003839 salts Chemical class 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 239000003637 basic solution Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- -1 dialkoxyalkanes Chemical class 0.000 description 2
- 150000001983 dialkylethers Chemical class 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000003511 tertiary amides Chemical class 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63313204P | 2004-12-03 | 2004-12-03 | |
| US60/633,132 | 2004-12-03 | ||
| PCT/US2005/043781 WO2006060730A2 (en) | 2004-12-03 | 2005-12-02 | Potassium salt of an hiv integrase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521933A JP2008521933A (ja) | 2008-06-26 |
| JP2008521933A5 true JP2008521933A5 (enExample) | 2010-12-24 |
| JP4705956B2 JP4705956B2 (ja) | 2011-06-22 |
Family
ID=36171569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544570A Expired - Lifetime JP4705956B2 (ja) | 2004-12-03 | 2005-12-02 | Ｈｉｖインテグラーゼ阻害剤のカリウム塩 |
Country Status (35)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1725528T3 (da) | 2004-03-11 | 2013-09-02 | 4Sc Ag | Sulfonylpyrroler som hdac-inhibitorer |
| JP5228488B2 (ja) * | 2004-12-03 | 2013-07-03 | メルク・シャープ・アンド・ドーム・コーポレーション | 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物 |
| MX2007006637A (es) * | 2004-12-03 | 2007-06-19 | Merck & Co Inc | Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa. |
| TR201907729T4 (tr) * | 2004-12-03 | 2019-06-21 | Merck Sharp & Dohme | Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. |
| US20090087492A1 (en) * | 2006-03-14 | 2009-04-02 | Merck & Co., Inc. | Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use |
| EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
| CA2702317A1 (en) * | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals, Inc. | Novel pyrimidinecarboxamide derivatives |
| CA2710987A1 (en) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Corp. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
| ES2549387T3 (es) * | 2009-06-02 | 2015-10-27 | Hetero Research Foundation | Procedimiento de preparación de raltegravir potásico amorfo |
| WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
| ES2898348T3 (es) | 2009-10-26 | 2022-03-07 | Merck Sharp & Dohme | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa |
| DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
| MY172005A (en) | 2009-12-07 | 2019-11-11 | Univ Georgia | Pyridinone hydroxycyclopentyl carboxamides : hiv integrase inhibators with therapeutic applications |
| ES2362598B1 (es) * | 2009-12-17 | 2012-06-13 | Consejo Superior De Investigaciones Científicas (Csic) | Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus. |
| CA2794952C (en) * | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| RU2012146517A (ru) | 2010-04-01 | 2014-05-10 | Тева Фармасьютикал Индастриз Лтд. | Соли ральтегравира и их кристаллические формы |
| EP2575465A4 (en) * | 2010-05-25 | 2013-11-20 | Hetero Research Foundation | Raltegravir SALTS |
| US9107922B2 (en) | 2010-07-16 | 2015-08-18 | Concert Pharmaceuticals, Inc. | Pyrimidinecarboxamide derivatives |
| CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
| JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
| WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
| WO2012106534A2 (en) * | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| EP2694497A1 (en) | 2011-04-06 | 2014-02-12 | Lupin Limited | Novel salts of raltegravir |
| CA2833006A1 (en) * | 2011-04-22 | 2012-10-26 | Merck Sharp & Dohme Corp. | Taste-masked formulations of raltegravir |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| EP2522665A1 (en) | 2011-05-03 | 2012-11-14 | Sandoz Ag | Crystalline sodium salt of an HIV integrase inhibitor |
| ES2450944T3 (es) | 2011-06-01 | 2014-03-25 | Ratiopharm Gmbh | Composición y comprimido que comprenden raltegravir |
| EP2755968A1 (de) | 2011-09-16 | 2014-07-23 | Hexal AG | Neue polymorphe form von raltegravir-kalium |
| CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| EP2804607B1 (en) | 2011-12-26 | 2020-09-16 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
| US20150328215A1 (en) | 2012-01-25 | 2015-11-19 | Lupin Limited | Stable amorphous raltegravir potassium premix and process for the preparation thereof |
| WO2014064711A2 (en) * | 2012-10-22 | 2014-05-01 | Hetero Research Foundation | Methods of administering raltegravir and raltegravir compositions |
| EP2818470A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | Cocrystals of raltegravir potassium |
| EP3022209B1 (en) | 2013-07-17 | 2018-03-07 | ratiopharm GmbH | Dolutegravir potassium salt |
| WO2015114608A1 (en) | 2014-02-03 | 2015-08-06 | Mylan Laboratories Ltd | Processes for the preparation of intermediates of raltegravir |
| EP3119773A1 (en) * | 2014-03-21 | 2017-01-25 | Mylan Laboratories Ltd. | A premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
| US10257840B2 (en) | 2014-10-22 | 2019-04-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Operation of wireless local area network in the presence of periodic interference |
| WO2016075605A1 (en) | 2014-11-10 | 2016-05-19 | Aurobindo Pharma Ltd | An improved process for the preparation of raltegravir |
| EP3472134B1 (en) * | 2016-06-21 | 2021-10-20 | Pharmathen S.A. | Process for preparing compounds useful as intermediates for the preparation of raltegravir |
| JP2019529410A (ja) * | 2016-09-15 | 2019-10-17 | ルピン・リミテッド | 純粋で安定な結晶のラルテグラビルカリウム３型の製造方法 |
| CN108610338A (zh) * | 2016-12-12 | 2018-10-02 | 天津国际生物医药联合研究院 | 一种嘧啶酮酰胺类化合物的制备方法 |
| ES2909302T3 (es) | 2017-11-14 | 2022-05-06 | Cambrex Profarmaco Milano S R L | Proceso para la preparación de Raltegravir |
| WO2019236395A1 (en) * | 2018-06-06 | 2019-12-12 | Merck Sharp & Dohme Corp. | Formulations of raltegravir |
| GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| US12465565B2 (en) | 2020-01-23 | 2025-11-11 | Lupin Limited | Pharmaceutical compositions of raltegravir |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624391A5 (enExample) * | 1976-12-14 | 1981-07-31 | Ciba Geigy Ag | |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5717097A (en) * | 1991-11-08 | 1998-02-10 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL121789A (en) * | 1996-10-03 | 2001-06-14 | Rohm & Haas | A medicinal product for inhibiting mammalian cell tumors |
| PL348596A1 (en) * | 1998-12-25 | 2002-06-03 | Shionogi & Co | Aromatic heterocycle compounds having hiv integrase inhibiting activities |
| IT1318424B1 (it) * | 2000-03-24 | 2003-08-25 | Unihart Corp | Composti con attivita' anti-hiv. |
| ATE430745T1 (de) | 2000-10-12 | 2009-05-15 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
| GB0028483D0 (en) * | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| DE60209381T2 (de) * | 2001-10-26 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| CN1596255A (zh) * | 2001-12-21 | 2005-03-16 | 阿诺麦德股份有限公司 | 具有强效的与趋化因子受体结合的杂环化合物 |
| WO2004046115A1 (ja) * | 2002-11-20 | 2004-06-03 | Japan Tobacco Inc. | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| BR0317749A (pt) * | 2002-12-27 | 2005-11-22 | Angeletti P Ist Richerche Bio | Composto, composição farmacêutica, e, uso de um composto |
| TW200423930A (en) * | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| JP5228488B2 (ja) * | 2004-12-03 | 2013-07-03 | メルク・シャープ・アンド・ドーム・コーポレーション | 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物 |
| MX2007006637A (es) | 2004-12-03 | 2007-06-19 | Merck & Co Inc | Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa. |
| TR201907729T4 (tr) | 2004-12-03 | 2019-06-21 | Merck Sharp & Dohme | Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. |
-
2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh not_active IP Right Cessation
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja not_active Expired - Lifetime
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 CA CA2588398A patent/CA2588398C/en not_active Expired - Lifetime
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/me unknown
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en not_active Expired
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Withdrawn
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en not_active IP Right Cessation
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh not_active Expired - Lifetime
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/en not_active Ceased
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 RS RS20120021A patent/RS52197B/sr unknown
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko not_active Expired - Lifetime
- 2005-12-02 EP EP05852866A patent/EP1819683B1/en not_active Expired - Lifetime
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/en not_active Ceased
- 2005-12-02 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es not_active Expired - Lifetime
- 2005-12-02 EP EP05852840A patent/EP1819700B1/en not_active Expired - Lifetime
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es not_active Expired - Lifetime
-
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
-
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en not_active Expired - Lifetime
-
2012
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
-
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6829304B2 (ja) | スガマデクスの調製のための改善されたプロセス | |
| JP2008510777A (ja) | メソトリオンの多形体を調製する方法 | |
| JP2010184925A (ja) | セフジニルの新規な結晶形 | |
| JP2020526476A (ja) | オメカムティブメカルビルの合成 | |
| BR112017008500B1 (pt) | Métodos para produção de praziquantel, seus sais diastereoméricos, e seu uso | |
| CN107635969A (zh) | 恩杂鲁胺结晶形式的制造方法 | |
| JP4538842B2 (ja) | 新規ナテグリニド結晶 | |
| JP2022514909A (ja) | アントラニルアミドの調製プロセス | |
| JP6228210B2 (ja) | フルボキサミン遊離塩基の精製方法およびそれを用いた高純度フルボキサミンマレイン酸塩の製造方法 | |
| JP4549531B2 (ja) | １，３−二置換−４−オキソ環式尿素の製造方法 | |
| CN105111188A (zh) | 一种埃索美拉唑镁三水合物晶型的制备方法 | |
| FR2959509A1 (fr) | Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole | |
| JP2017095453A (ja) | 高純度フルオレセインナトリウム | |
| JP4514950B2 (ja) | １，３−二置換−４−オキソ環式尿素の製造方法 | |
| JP4655930B2 (ja) | キノリンカルボン酸誘導体溶媒和物の結晶 | |
| JP2014515381A (ja) | エピルビシン塩酸塩の結晶化 | |
| JPS6151596B2 (enExample) | ||
| JP2012506877A (ja) | エリスロマイシンの結晶化方法 | |
| JP4514017B2 (ja) | 塩酸エピナスチンの製造方法 | |
| RU2238272C1 (ru) | Способ получения 1-алкил-6,6-диметил-2,4-диоксо-2,3,4,5,6,7-гексагидро-1h-индол-3-спиро-2-( 1-арил-3-ароил-4-гидрокси-5-оксо-2,5-дигидропирролов) | |
| EA008883B1 (ru) | Способ получения хирально чистого n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланина и его кристаллических модификаций | |
| KR20070053697A (ko) | 개선된 미르타자핀 제조방법 | |
| EA011763B1 (ru) | Способы получения венлафаксина и формы i венлафаксина гидрохлорида | |
| JPH06340599A (ja) | 光学活性２−アミノ酪酸の製法 | |
| US20050272802A1 (en) | Process for preparing form I of tegaserod maleate |